



Institutional Review Board (IRB) Fee Schedule

Effective Date: February 1, 2026

Review Type	Fee	Description
Initial Submission (Full Board or Expedited)	\$3,500	Covers full IRB review of industry-sponsored protocols, including preparation, committee review, and documentation.
Multi-Site Initial Submission (per additional site)	\$1,500	Charged for each additional site beyond the lead site.
Sub-Study Fee	\$1,000	Charged per sub-study per site, either with a new submission or added to an approved study.
Continuing Review Submission	\$1,750	Annual continuing review of active protocols.
Multi-Site Continuing Review (per additional site)	\$1,000	Charged for each additional site beyond the lead site.
Amendments Requiring Full Board Review	\$1,500	Covers IRB review of sponsor-initiated amendments requiring full board consideration.
Multi-Site Amendment (per additional site)	\$750	Charged for each additional site beyond the lead site.
Annual Status Report	\$1,000	Charged for annual status updates when continuing review is not required.
Request to Use / Cede to External IRB (Administrative Review)	\$2,000	Covers institutional administrative review when McLaren cedes oversight to an external IRB. This includes verification of reliance agreements, HIPAA authorization review, AAHRPP compliance, and confirmation that study personnel have appropriate training, education, and experience to meet



		institutional and regulatory requirements prior to study activation.
Final Report / Study Close-Out	\$1,000	Covers IRB closure documentation and final reporting.
Protocol Deviations / Violations	\$0	No fee charged.
Unanticipated Problems Involving Risk	\$0	No fee charged
Optional Fixed Fee (covers all reviews and close-out)	\$6,000	Provides a one-time, comprehensive payment option that covers the initial submission, all amendments, continuing reviews, and study close-out for the duration of the study.

IRB Fee Policy Statement

The McLaren Health Care Institutional Review Board (MHC IRB) charges for the review and oversight of human subject research studies supported by pharmaceutical, medical device, and other for-profit entities. Investigators submitting industry-sponsored research protocols are required to include in the study budget the cost of initial protocol review, continuing review, and sponsor-initiated full-board amendments requiring IRB review.

IRB operations are specialized and rigorously regulated, and fees are based on the assessment of costs associated with protocol review. All IRB fees are mandatory, non-refundable, and billed directly to the sponsor. These charges apply regardless of whether the study is ultimately approved, whether participants are enrolled, or whether the study is terminated before completion. Fee payments are expected to be paid in full within 30 days of invoice.

The IRB does not assess review fees for federally funded research, graduate medical education projects, or student-initiated studies, as these activities are exempt from IRB billing in order to comply with federal cost principles and to support the educational mission of the Institution.